Warning Letter: Watson Labs

News
Article

ePT--the Electronic Newsletter of Pharmaceutical Technology

On July 18, the US Food and Drug Administration posted a Warning Letter issued Watson Laboratories Caribe, Inc. (Corona, CA) by FDA's San Juan (PR) district office.

On July 18, the US Food and Drug Administration posted a Warning Letter issued Watson Laboratories Caribe,Inc. (Corona, CA) by FDA's San Juan (PR) district office. The Warning,dated June 19, cited manufacturing deficiencies at Watson'sHumacao, Puerto Rico facility. According to the letter, a Nov.3–Dec.15, 2005, FDA inspection uncovered significant deviations from currentgood manufacturing practice (CGMP) regulations including:

  • The company's "inadequate" handling and identification of sievedmaterials could have caused an incorrect component or active ingredientto be used in the manufacture of drug products (21 CFR Part 211.80 [a]). The WarningLetter listed the mislabeling of the active ingredient, trazodone HClsalt, as lactose. The ingredient was then used during the manufactureof clindamycin HCl antibiotic capsules. The lots were rejected, butothers that were manufactured in the same equipment were released withonly minor cleaning.

  • Laboratory controls did not include appropriate test proceduresto ensure in-process materials and drug products conform to identity,strength, quality, and purity standards (21 CFR Part 211.160[b]). For example,the letter noted that numerous changes were made to the dissolutiontesting process of the "Reclipsen" oral contraceptive within one yearwithout additional validation. The letter said FDA has "no assurancethat the current method is able to consistently produce precise andaccurate results."

FDA recommended Watson Laboratories, "take prompt action to correctthese violations, and you should establish procedures whereby suchviolations do not recur. Failure to do so may result in regulatoryaction without further notice, including seizure and/or injunction."

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes